Pediatrics Spanish Registry of Percutaneous Melody Pulmonary Valve Implantation in Patients Younger Than 18 Years

Solana-Gracia, Ruth; Rueda, Fernando Moya; Betrián, Pedro; Gutiérrez-Larraya, Federico; Cerro, María Jesús del; Pan, Manuel; Alcibar, Juan; Coserria, Jose F.; Velasco, Josè M.; Zunzunegui, José Luis

doi:10.1016/j.rec.2017.07.013

Cited by 4 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First described in September 2000, percutaneous pulmonary valve implantation (PPVI) offers an attractive alternative to surgical pulmonary valve replacement (sPVR) [ 2 ]. Percutaneous valves have demonstrated beneficial hemodynamic effects and a seemingly favorable short- and medium-term safety profile in both adult [ 3 – 9 ] and pediatric cohorts [ 10 , 11 ]. However, some series reported an increase in the incidence of premature ventricular contractions (PVC) and non-sustained ventricular tachycardia (NSVT) immediately after the procedure, which mostly resolved by 6 months of follow-up [ 12 – 14 ].…”

Section: Introductionmentioning

confidence: 99%

Ventricular Arrhythmias and Sudden Death Following Percutaneous Pulmonary Valve Implantation in Pediatric Patients

et al. 2022

View full text Add to dashboard Cite

Reports have suggested a transient increase in ventricular ectopy early after percutaneous pulmonary valve implantation (PPVI). Little is known about the potential for more serious ventricular arrhythmias (VA) in children who undergo PPVI. We sought to evaluate the incidence of severe VA following PPVI in a pediatric population and to explore potential predictive factors. A retrospective cohort study was conducted of patients who underwent PPVI under 20 years of age in our institution from January 2007 to December 2019. The primary outcome of severe VA was defined as sustained and/or hemodynamically unstable ventricular tachycardia (VT), inducible sustained VT, or sudden death of presumed arrhythmic etiology. A total of 21 patients (mean age 16.2 ± 2.1 years; 66.7% male) underwent PPVI. The majority of patients (N = 15; 71.4%) had tetralogy of Fallot (TOF) or TOF-like physiology, with the most common indication being pulmonary insufficiency (N = 10; 47.6%). During a median follow-up of 29.6 months (IQR 10.9–44.0), severe VA occurred in 3 (14.3%) patients aged 15.6 (IQR 14.7–16.1) a median of 12.3 months (IQR 11.2–22.3) after PPVI. All events occurred in patients with TOF-like physiology following Melody valve implant. In conclusion, severe VA can occur long after PPVI in a pediatric population, particularly in those with TOF-like physiology. Further studies are required to elucidate underlying mechanisms and assess strategies to mitigate risks.

show abstract

Section: Introductionmentioning

confidence: 99%

Ventricular Arrhythmias and Sudden Death Following Percutaneous Pulmonary Valve Implantation in Pediatric Patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…El tratamiento actual de las cardiopatías congénitas, junto con el avance de las técnicas de imagen no invasivas, el desarrollo de nuevos procedimientos quirúrgicos y el intervencionismo hemodinámico, ha contribuido al incremento de la sobrevida de los pacientes, pero también a la necesidad de mayores reintervenciones 1 . Por esa razón es importante aplicar nuevas técnicas que reduzcan la morbimortalidad y favorezcan un mayor tiempo sin intervenciones.…”

Section: Introductionunclassified

Implante percutáneo de válvula pulmonar: a propósito de dos casos colombianos

Díaz¹,

Lince²,

Hernández³

et al. 2020

ACM

View full text Add to dashboard Cite

Los pacientes con cardiopatías congénitas que afectan la continuidad del ventrículo derecho con la arteria pulmonar deben someterse con frecuencia a intervenciones debido a la limitada vida útil de los conductos quirúrgicos, lo que lleva al desarrollo de disfunción ventricular derecha por cambios en la geometría ventricular y predisposición a arritmias letales, con el consiguiente riesgo de reintervenciones. El implante valvular percutáneo pulmonar es una nueva alternativa terapéutica, menos invasiva en comparación con la quirúrgica, para pacientes seleccionados. Se realiza una revisión de las publicaciones médicas actuales disponibles y se describe la experiencia inicial del implante valvular pulmonar percutáneo en un centro colombiano de alta complejidad para el tratamiento de enfermedades cardiovasculares, en dos pacientes con disfunción del homoinjerto aórtico en posición pulmonar con doble lesión valvular, en los cuales el implante valvular pulmonar percutáneo fue una conducta exitosa. Se eligió a pacientes con cardiopatías congénitas, conductos quirúrgicos disfuncionales con estenosis o insuficiencia pulmonar significativa, y disfunción y dilatación ventricular derechas. Se empleó la técnica regular para el implante de la válvula pulmonar Melody, sin documentarse complicaciones durante el procedimiento ni al año de seguimiento. El implante percutáneo de la válvula pulmonar es un gran avance en el tratamiento de pacientes con cardiopatías congénitas, con resultados favorables a corto y mediano plazos, lo cual hace posible la restauración de la función ventricular con riesgo mínimo, frente al reemplazo quirúrgico en pacientes seleccionados.

show abstract

“…Current treatment of congenital heart disease, along with the advances in non-invasive imaging techniques, the development of new surgical procedures, and hemodynamic interventionism, has contributed to an increase in patient survival, but also to the need for more reoperations 1 . For that reason, it is important to apply new techniques that reduce morbidity and mortality and favor longer periods free of interventions.…”

Section: Introductionmentioning

confidence: 99%

Percutaneous pulmonary valve implant: two Colombian case reports

Díaz¹,

Lince²,

Hernández³

et al. 2020

ACME

View full text Add to dashboard Cite

Patients with congenital heart disease that involves reconstruction of the right ventricular (RV) outflow tract must frequently undergo interventions derived from the limited useful life of the surgical canals, which leads to the development of RV dysfunction due to changes in the ventricular geometry and predisposition to lethal arrhythmias, with the consequent risk of reinterventions. The percutaneous pulmonary valvular implant is a new therapeutic alternative, less invasive, compared to surgery, for selected patients. A review of the available literature is made, and the initial experience of percutaneous pulmonary valve implantation in a Colombian center of high complexity for the treatment of cardiovascular diseases is described, in two patients with aortic homograft dysfunction in a pulmonary position with double valvular lesion, in which the percutaneous pulmonary valve implant was a successful strategy. Patients with congenital heart disease were chosen, with dysfunctional surgical conduits with stenosis or significant pulmonary insufficiency, with dysfunction and RV dilatation. The standard technique for the implantation of the Melody pulmonary valve was used without complications during the procedure or 1 year of follow-up. Percutaneous implantation of the pulmonary valve is a great advance in the management of patients with congenital heart diseases, with favorable results in the short and medium-term, allowing the restoration of ventricular function with minimal risk, compared to surgical replacement in selected patients.

show abstract

Pediatrics Spanish Registry of Percutaneous Melody Pulmonary Valve Implantation in Patients Younger Than 18 Years

Cited by 4 publications

References 38 publications

Ventricular Arrhythmias and Sudden Death Following Percutaneous Pulmonary Valve Implantation in Pediatric Patients

Ventricular Arrhythmias and Sudden Death Following Percutaneous Pulmonary Valve Implantation in Pediatric Patients

Implante percutáneo de válvula pulmonar: a propósito de dos casos colombianos

Percutaneous pulmonary valve implant: two Colombian case reports

Contact Info

Product

Resources

About